US Patent

US8283380 — Methods for treatment of parkinson's disease

Method of Use · Assigned to Newron Pharmaceuticals SpA · Expires 2031-03-21 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating Parkinson's Disease by administering safinamide, a safinamide derivative, or a MAO-B inhibitor in combination with other Parkinson's Disease agents or treatments.

USPTO Abstract

New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1993 — safinamide-mesylate
U-1993 — safinamide-mesylate

Patent Metadata

Patent number
US8283380
Jurisdiction
US
Classification
Method of Use
Expires
2031-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Newron Pharmaceuticals SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.